Economic burden of human papilloma virus related diseases in China: a systematic review and synthetic analysis

HE Ni-nan; ZOU Zhuo-ru; ZHANG Yun-bo; HE Xiao-qing; XIONG Su-qiang; LIU Chang-xin; BAO Jia-wei; XIA Ru-yi; ZHUANG Gui-hua

doi:10.16462/j.cnki.zhjbkz.2023.03.018

Volume 27 Issue 3

Mar. 2023

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2023 > 27(3): 345-351

HE Ni-nan, ZOU Zhuo-ru, ZHANG Yun-bo, HE Xiao-qing, XIONG Su-qiang, LIU Chang-xin, BAO Jia-wei, XIA Ru-yi, ZHUANG Gui-hua. Economic burden of human papilloma virus related diseases in China: a systematic review and synthetic analysis[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(3): 345-351. doi: 10.16462/j.cnki.zhjbkz.2023.03.018

Citation:

HE Ni-nan, ZOU Zhuo-ru, ZHANG Yun-bo, HE Xiao-qing, XIONG Su-qiang, LIU Chang-xin, BAO Jia-wei, XIA Ru-yi, ZHUANG Gui-hua. Economic burden of human papilloma virus related diseases in China: a systematic review and synthetic analysis[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(3): 345-351. doi: 10.16462/j.cnki.zhjbkz.2023.03.018

Citation:

HE Ni-nan, ZOU Zhuo-ru, ZHANG Yun-bo, HE Xiao-qing, XIONG Su-qiang, LIU Chang-xin, BAO Jia-wei, XIA Ru-yi, ZHUANG Gui-hua. Economic burden of human papilloma virus related diseases in China: a systematic review and synthetic analysis[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(3): 345-351. doi: 10.16462/j.cnki.zhjbkz.2023.03.018

PDF( 1068 KB)

Economic burden of human papilloma virus related diseases in China: a systematic review and synthetic analysis

doi: 10.16462/j.cnki.zhjbkz.2023.03.018

1.
Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an 710061, China
2.
Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an 710061, China

HE Ni-nan and ZOU Zhuo-ru contributed equally to this work

Funds:

Xi'an Preventive Medical Association 2020-12-0001

More Information

Corresponding author: ZHUANG Gui-hua, E-mail: zhuanggh@mail.xjtu.edu.cn
Received Date: 2022-05-07
Rev Recd Date: 2022-09-25

Available Online: 2023-04-04

Publish Date: 2023-03-10

Abstract

Abstract

Objective To integrate cost-related data of human papilloma virus (HPV) related diseases from Mainland China and estimate the economic burden. Methods We uesd "Cost/expense" combined with names of the nine major HPV-related diseases, i.e. cervical cancer, vaginal cancer, vulva cancer, anal cancer, penile cancer, oropharyngeal cancer, cervical intraepithelial neoplasia (CIN), anogenital warts (AGW), and recurrent respiratory papillomatosis (RRP), as keywords. Seven databases including PubMed and China National Knowledge Infrastructure were selected, for literature targeting patients in mainland China published between 2001-2020. Various cost-related data were extracted, and cost data were adjusted annually to 2020 according to appropriate consumer price indices. Data were used to estimate per-capita direct medical costs, direct non-medical costs, and indirect costs for each of the nine diseases. The incidence, prevalence, and HPV attribution fraction of each of the nine diseases were collected to further estimate the total economic burden of HPV-related diseases in Mainland China in 2020. Results A total of 247 articles were included. Annual per-capita total costs of each of the six cancers ranged from 58 189 to 79 567 yuan in the first year of the disease and from 13 025 to 27 965 yuan in each subsequent year. Annual per-capita total costs of RRP were 41 329 yuan. Per-capita total costs of CIN and AGW ranged between 6 452 and 13 602 yuan. The total economic burden due to HPV-related diseases in Mainland China in 2020 was about 18.03 billion yuan, with cervical cancer accounting for 9.69 billion yuan. Direct medical costs were a significant part of the economic burden, accounting for 70% of the total burden, with 7.0 billion yuan in direct medical costs due to cervical cancer. Conclusions The annual economic burden of HPV-related diseases in Mainland China cannot be ignored. Scaling up HPV vaccination is needed to reduce associated economic losses.
- Human papilloma virus,
- Economic burden,
- Synthetic analysis

FullText(HTML)

References(22)

References

[1]	de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type[J]. Int J Cancer, 2017, 141(4): 664-670. DOI: 10.1002/ijc.30716.
[2]	Östensson E, Silfverschiöld M, Greiff L, et al. The economic burden of human papillomavirus-related precancers and cancers in Sweden[J]. PLoS One, 2017, 12(6): e0179520. DOI: 10.1371/journal.pone.0179520.
[3]	Ki M, Choi HY, Han M, et al. The economic burden of human papillomavirus infection-associated diseases in the Republic of Korea, 2002-2015[J]. Vaccine, 2018, 36(31): 4633-4640. DOI: 10.1016/j.vaccine.2018.06.046.
[4]	赵艳霞, 马兰, 任文辉, 等. 2009―2018年中国农村妇女宫颈癌检查项目数据分析[J]. 中华医学杂志, 2021, 101(24): 1863-1868. DOI: 10.3760/cma.j.cn112137-20210111-00075. Zhao YX, Ma L, Ren WH, et al. Analysis of the reported data of national cervical cancer screening program in rural areas in China from 2009 to 2018[J]. Natl Med J China, 2021, 101(24): 1863-1868. DOI: 10.3760/cma.j.cn112137-20210111-00075.
[5]	Ma X, Wang Q, Ong JJ, et al. Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis[J]. Sex Transm Infect, 2018, 94(6): 434-442. DOI: 10.1136/sextrans-2017-053412.
[6]	岳晓丽, 龚向东, 李婧, 等. 2008―2016年中国性病监测点尖锐湿疣流行特征分析[J]. 中华皮肤科杂志, 2017, 50(5): 321-325. DOI: 10.3760/cma.j.issn.0412-4030.2017.05.003. Yue XL, Gong XD, Li J, et al. Epidemiological features of condyloma acuminatum in national sexually transmitted disease surveillance sites in China from 2008 to 2016[J]. Chin J Dermatol, 2017, 50(5): 321-325. DOI: 10.3760/cma.j.issn.0412-4030.2017.05.003.
[7]	Zhu B, Liu Y, Zuo T, et al. The prevalence, trends, and geographical distribution of human papillomavirus infection in China: the pooled analysis of 1.7 million women[J]. Cancer Med, 2019, 8(11): 5373-5385. DOI: 10.1002/cam4.2017.
[8]	Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States[J]. Am J Obstet Gynecol, 2008, 198(5): 500. e1-500. e7. DOI: 10.1016/j.ajog.2008.03.064.
[9]	World Health Organization. Questions and answers about human papillomavirus (HPV)[EB/OL]. (2020-09-30)[2021-12-01]. https://www.who.int/europe/publications/i/item/WHO-EURO-2020-5631-45396-64962.
[10]	Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis[J]. Lancet Glob Health, 2016, 4(9): e609-e616. DOI: 10.1016/S2214-109X(16)30143-7.
[11]	Serrano B, Brotons M, Bosch FX, et al. Epidemiology and burden of HPV-related disease[J]. Best Pract Res Clin Obstet Gynaecol, 2018, 47: 14-26. DOI: 10.1016/j.bpobgyn.2017.08.006.
[12]	Chen G, Zheng P, Gao L, et al. Prevalence and genotype distribution of human papillomavirus in women with cervical cancer or cervical intraepithelial neoplasia in Henan Province, central China[J]. J Med Virol, 2020, 92(12): 3743-3749. DOI: 10.1002/jmv.25670.
[13]	Wang W, An J, Song Y, et al. Distribution and attribution of high-risk human papillomavirus genotypes in cervical precancerous lesions in China[J]. Tumour Biol, 2017, 39(7): 101042831770737. DOI: 10.1177/1010428317707373.
[14]	万晓春, 周晓燕, 平波, 等. 九价HPV疫苗所针对的高危型HPV亚型在宫颈癌及其癌前病变中应用有效性的初步预测[J]. 中国癌症杂志, 2017, 27(7): 552-558. DOI: 10.19401/j.cnki.1007-3639.2017.07.006. Wan XC, Zhou XY, Ping B, et al. Preliminary prediction of the effectiveness of high-risk HPV types included 9-valent HPV vaccine in uterine cervical cancers and precancerous lesions[J]. Chin Oncol, 2017, 27(7): 552-558. DOI: 10.19401/j.cnki.1007-3639.2017.07.006.
[15]	石菊芳, 石春雷, 岳馨培, 等. 1996-2014年中国恶性肿瘤经济负担的系统评价[J]. 中华肿瘤杂志, 2016, 38(12): 929-941. DOI: 10.3760/cma.j.issn.0253-3766.2016.12.010. Shi JF, Shi CL, Yue XP, et al. Economic burden of cancer in China during 1996-2014: a systematic review[J]. Chinese Journal of Oncology, 2016, 38(12): 929-941. DOI: 10.3760/cma.j.issn.0253-3766.2016.12.010.
[16]	Zou Z, Fairley CK, Ong JJ, et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis[J]. Lancet Glob Health, 2020, 8(10): e1335-e1344. DOI: 10.1016/S2214-109X(20)30277-1.
[17]	何嫒萍, 匡真良, 莫凤志, 等. 广西梧州农村妇女宫颈癌careHPV筛查方案的卫生经济学评价[J]. 实用妇科内分泌电子杂志, 2019, 6(26): 48-50. DOI: 10.16484/j.cnki.issn2095-8803.2019.26.032. He AP, Kuang ZL, Mo FZ, et al. Health economics evaluation of careHPV screening program for cervical cancer in rural women in Wuzhou, Guangxi[J]. Electronic Journal of Practical Gynecological Endocrinology, 2019, 6(26): 48-50. DOI: 10.16484/j.cnki.issn2095-8803.2019.26.032.
[18]	孙雨欣, 刘永军, 刘通. 宫颈癌疫苗用于18~25岁中国女性预防宫颈癌的药物经济学评价[J]. 中国循证医学杂志, 2017, 17(1): 102-107. DOI: 10.7507/1672-2531.201610004. Sun YX, Liu YJ, Liu T. Economic evaluation of human papillomavirus vaccine versus Chinese women aged 18 to 25 for treating cervical cancer[J]. Chin J Evid Based Med, 2017, 17(1): 102-107. DOI: 10.7507/1672-2531.201610004.
[19]	张倩. 子宫颈癌筛查的风险分流及疫苗的卫生经济学评价研究[D]. 北京: 北京协和医学院, 2017. Zhang Q. The triage and risk management of cervical cancer screening and cost-effective analysis of vaccine[D]. Beijing: Peking Union Medical College, 2017.
[20]	宋晓彬, 赵勤俭, 周鼒, 等. 二价HPV疫苗接种策略的卫生经济学评估: 基于动态模型[J]. 中华预防医学杂志, 2017, 51(9): 814-820. DOI: 10.3760/cma.j.issn.0253-9624.2017.09.008. Song XB, Zhao QJ, Zhou Z, at al. Health economic evaluation of bivalent human papilloma virus vaccine in China: based on the dynamic model[J]. Chin J Prev Med, 2017, 51(9): 814-820. DOI: 10.3760/cma.j.issn.0253-9624.2017.09.008.
[21]	Ma X, Harripersaud K, Smith K, et al. Modeling the epidemiological impact and cost-effectiveness of a combined schoolgirl HPV vaccination and cervical cancer screening program among Chinese women[J]. Hum Vaccin Immunother, 2021, 17(4): 1073-1082. DOI: 10.1080/21645515.2020.1832835.
[22]	WHO. Human papillomavirus vaccines: WHO position paper (2022 update)[J]. Wkly Epidemiol Rec, 2022, 97: 645-672.